Carmer Scott 4
4 · NexImmune, Inc. · Filed Feb 19, 2021
Insider Transaction Report
Form 4
NexImmune, Inc.NEXI
Carmer Scott
DirectorPresident and CEO
Transactions
- Conversion
Common Stock
2021-02-17+7,058→ 7,058 total - Conversion
Series A Preferred Stock
2021-02-17−7,058→ 0 total→ Common Stock (7,058 underlying)
Footnotes (3)
- [F1]The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis.
- [F2]The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering.
- [F3]Not applicable.